Molecular profiling of spinal ependymomas reveals distinct subtypes with varying prognoses, enhancing treatment strategies (ref: Hack doi.org/10.1093/neuonc/).
DNA methylation-based modeling in meningiomas predicts outcomes and integrates into clinical practice, improving decision-making (ref: Landry doi.org/10.1093/neuonc/).
The G2019S LRRK2 mutation exacerbates neurodegeneration in Parkinson's disease through divergent pathways, indicating potential therapeutic targets (ref: Tsafaras doi.org/10.1007/s00401-025-02956-6/).
TMEM106B genetic variation influences microglial activation in CTE, linking genetic predispositions to inflammatory responses (ref: Hartman doi.org/10.1007/s00401-025-02955-7/).
The HAEEPGP peptide shows promise in suppressing β-amyloid pathology, addressing limitations of current monoclonal antibody therapies (ref: Kechko doi.org/10.1007/s12035-025-05349-8/).
The Neighborhoods Study links adverse social exposures to brain health, emphasizing the role of environmental factors in dementia (ref: George doi.org/10.1002/alz.70810/).
Proteomic profiling reveals mitochondrial dysregulation in rapidly progressive Alzheimer's disease, highlighting metabolic pathways as therapeutic targets (ref: Zafar doi.org/10.1007/s12035-025-05327-0/).
BTK inhibition limits inflammation in multiple sclerosis models while promoting regulatory B cell functions, suggesting a novel therapeutic strategy (ref: Dybowski doi.org/10.1212/NXI.0000000000200510/).